Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CRVS · NASDAQ · Pharmaceutical Preparations
Corvus Pharmaceuticals (CRVS) · oqro.io/stocks/CRVS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$10.64+0.02 (+0.19%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Traded Nov 11 – Nov 13, 2026 · largest single transaction ~$34K
Nov 12, 2026~$5.5K · 497 sh @ $11.12
DetailsOfficial recordNov 13, 2026~$5.2K · 503 sh @ $10.37
DetailsOfficial recordNov 13, 2026~$5.4K · 500 sh @ $10.71
DetailsOfficial recordOrbimed Advisors Llc (Director) sold ~$4.89M of Corvus Pharmaceuticals
Automatic salePeter A. Thompson (Director) sold ~$4.89M of Corvus Pharmaceuticals
Automatic saleNov 11, 2026~$34K · 3,000 sh @ $11.46
4 open-market purchases and 0 open-market sales by insiders of CRVS between Feb 10, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 5, 2026. The data provider lists the next release for Mar 10, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 5, 2026 | None | None | 4 purchases |
| Aug 6, 2026 | None | None | None |
| May 7, 2026 | None | None | None |
| Mar 12, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
